Navigation Links
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
Date:7/11/2014

SARASOTA, Fla., July 11, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), an emerging biotechnology company, today announced that the Food and Drug Administration ("FDA"), has notified the Company that the agency will provide comments on RCP's Investigational New Drug ("IND") application before granting the Company permission to start its clinical trial in the US.

Dr. Chris Chapman, RCP's President, commented, "We appreciate the agency's review and comments on our IND. When we receive the agency's official comments and/or recommendations, we will respond expeditiously. We look forward to moving this important product through the regulatory process."

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical dietary supplements products, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and
'/>"/>

SOURCE Rock Creek Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. AMG Medical Inc. Selects Saddle Creek for Multichannel Fulfillment
2. A Forever Recovery Battle Creek, MI: Increasing Recreational Drug Use in Colleges Creates Risk for Addictions
3. Creekridge Capital Continues Vendor Growth within Technology
4. Star Scientific and Rock Creek Pharmaceuticals Report on the Beneficial Nutritional Effects of Anatabine in an Animal Model of Ulcerative Colitis
5. Creekridge Capital Announces Record Volume
6. Creekridge Capital Adds Revolving Credit Specialist
7. Creekridge Capital Expands Healthcare Sales Team
8. Creekridge Capital Launches Vendor Sales Training Program
9. Creekridge Capital Grows Healthcare Sales Team
10. Creekridge Breaks Monthly and Quarterly Volume Records
11. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), ... as XIAFLEX ® in the U.S. and XIAPEX ® ... Tom Wegman , will present at the following upcoming investor ... & Renshaw 16 th Annual Global Investment ... September 9, 2014 at 9:10 a.m. EDT , ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014 /PRNewswire/ ... an oncology company focused on the clinical development ... it has completed enrollment in a randomized Phase ... candidate Pracinostat in combination with azacitidine in patients ... (MDS). The multi-center, placebo-controlled, double-blind study enrolled a ...
(Date:9/2/2014)... ANTONIO , Sept. 2, 2014 ... medical technology company focused on innovating lifesaving devices ... the appointment of Dr. Gabriele Niederauer , ... and CEO. Following the recent closure of Series ... Mark for the Surfacer™ Inside-Out Access Catheter System, ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 4Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2
... THOUSAND OAKS, Calif., Sept. 24 Amgen (Nasdaq: ... EPOGEN® and PROCRIT® (Epoetin alfa) vials are being voluntarily ... as a precaution.  The product that is being recalled ... barely visible in most cases. The lamellae result from ...
... Pharmasset, Inc. (Nasdaq: VRUS ) announces that management ... September 27-28, 2010 at the New York Palace Hotel, New ... will provide an overview of the company at the JMP ... To access a simultaneous webcast of Mr. Price,s ...
Cached Medicine Technology:Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 2Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 3Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 4Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 5Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 6Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 7Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 8Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 9Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 10Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 11Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 12Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 13Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 14Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 15Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 16Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 17Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 18Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 19Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 20Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 21Pharmasset to Present at the JMP Healthcare Conference 2Pharmasset to Present at the JMP Healthcare Conference 3
(Date:9/2/2014)... (PRWEB) September 02, 2014 - Molecular ... as a class of diagnostic test that analyzes proteins ... nucleic acids and proteins that belong to individual patients ... health condition, or risk of developing a specific disease. ... known as (MDx) evaluating the new class of diagnostic ...
(Date:9/2/2014)... A little white pill may help scientists learn ... than their peers, even if their lungs are relatively ... marketed as Revatio to treat pulmonary hypertension and ... cocktail of over-the-counter antioxidants will help them identify the ... difficult for these patients. , "We want to ...
(Date:9/2/2014)... The Society of Nuclear Medicine and Molecular Imaging (SNMMI) ... SNMMI Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 ... the late Kanji Torizuka, MD, PhD, is designed to ... nuclear medicine and molecular imaging for Japanese physicians in ... "SNMMI is proud to sponsor the Wagner-Torizuka Fellowship. This ...
(Date:9/2/2014)... 2014 Vertebral invasive compression fractures called ... vertebrae in our spine suffers crack or gets deformed. ... in people with osteoporosis or low bone density. Though ... forms of metastatic tumors and extensive trauma such as ... can also lead to such fractures. , The placement ...
(Date:9/2/2014)... 02, 2014 Concorde Career College ... to receive the 2014 Excellence in Community Service ... and Colleges (ACCSC). , Every year, the Accrediting ... members who make outstanding contributions in their local ... for the scope and impact of the community ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 2Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 3Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 4Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:SNMMI 2014-2016 Wagner-Torizuka Fellowship recipients announced 2Health News:An Overview of the Minimally Invasive Vertebral Compression Fracture Repair Market by Transparency Market Research 2Health News:An Overview of the Minimally Invasive Vertebral Compression Fracture Repair Market by Transparency Market Research 3Health News:Concorde Career College North Hollywood Awarded 2014 Excellence in Community Service Award 2
... HealthDay Reporter , TUESDAY, July 27 (HealthDay News) -- ... lost? Seeking out the right Web site might help, a ... logged on to a specially designed Internet site for weight maintenance ... loss than people who logged on less often, new research finds. ...
... HealthDay Reporter , MONDAY, July 26 (HealthDay News) -- An ... to help severely disabled people play computer games, express themselves ... experimental "sniff controller" takes advantage of the fact that cranial ... still able to send messages to the soft palate (the ...
... (BRONX, NY) For the third time in four months, ... the National Institutes of Health (NIH) has awarded Albert Einstein ... at helping people infected with multidrug-resistant tuberculosis (MDR-TB). ... The latest awardee Neel Gandhi, M.D. , assistant ...
... that patients often exhibit a significant decrease in weight and body ... The study is the first of its type to correct ... between the ages of 29 to 73 years. The study ... of 196 Mount Sinai patients who had knee or hip replacement ...
... What,s a baseball game or a football game or a ... offer a staggering array of food from appetizers to desserts. But ... beer. A special news media briefing and reception will focus ... 240th National Meeting & Exposition , which be held here ...
... 2010) A major research company affiliated with the ... is partnering with the University of Colorado,s Anschutz Medical ... discoveries from the laboratory to the patient. CPC, formally ... the University Physicians Incorporated building across the street from ...
Cached Medicine News:Health News:To Help Keep Weight Off, Turn to the Web 2Health News:To Help Keep Weight Off, Turn to the Web 3Health News:Sniffing Device Allows Disabled to Write, Run Wheelchairs 2Health News:Sniffing Device Allows Disabled to Write, Run Wheelchairs 3Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 2Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 3Health News:Many knee and hip replacement patients experience weight decrease after surgery 2Health News:Special news media briefing and reception during American Chemical Society national meeting 2Health News:University of Colorado joins forces with major research affiliate 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: